Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort

HIV-1 nucleoside/tide reverse transcriptase inhibitors (NRTI)-only based, comprising tenofovir DF(TDF) have been shown to lead to high rates of virological failures (VF), mainly in patients on first-line combination therapy. We wished to investigate the virological response to these regimens in a la...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical virology 2006-06, Vol.36 (2), p.95-99
Main Authors: Balestre, Eric, Dupon, Michel, Capdepont, Sophie, Thiébaut, Rodolphe, Boucher, Sébastien, Fleury, Hervé, Dabis, François, Masquelier, Bernard
Format: Article
Language:English
Subjects:
Adenine - analogs & derivatives
Adenine - therapeutic use
Biological and medical sciences
Cohort Studies
Didanosine - therapeutic use
Dideoxynucleosides - therapeutic use
Drug Therapy, Combination
France
Fundamental and applied biological sciences. Psychology
HIV Infections - drug therapy
HIV Infections - virology
HIV Reverse Transcriptase - genetics
HIV-1 - drug effects
HIV-1 - genetics
HIV-1 - isolation & purification
HIV-1 drug resistance
Hospitals, University
Human immunodeficiency virus 1
Human viral diseases
Humans
Infectious diseases
Lamivudine - therapeutic use
Medical sciences
Microbiology
Miscellaneous
Mutation
Nucleoside reverse transcriptase inhibitors
Organophosphonates - therapeutic use
Retrospective Studies
Reverse Transcriptase Inhibitors - therapeutic use
Species Specificity
Tenofovir
Treatment Outcome
Viral diseases
Viral Load
Virological response
Virology
Zidovudine - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:HIV-1 nucleoside/tide reverse transcriptase inhibitors (NRTI)-only based, comprising tenofovir DF(TDF) have been shown to lead to high rates of virological failures (VF), mainly in patients on first-line combination therapy. We wished to investigate the virological response to these regimens in a large cohort of antiretroviral (ARV)-treated patients. Patients followed-up in the Aquitaine Cohort in 2001–2003 and who had received NRTI-based, TDF-including regimens for at least 3 months were included. The VF was defined as: (i) a decrease in plasma HIV-1 RNA 50 copies/ml at M3 in patients with plasma HIV-1 RNA
ISSN:1386-6532
1873-5967
DOI:10.1016/j.jcv.2006.02.002